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Abstract 
Background: Anticoagulation therapy is used in several conditions to prevent or treat thromboembolism. A new 
group of oral anticoagulants with clear advantages over classic dicoumarin oral anticoagulants (warfarin and ace-
nocoumarol) has been developed in recent years. The Food and Drug Administration has approved edoxaban, da-
bigatran, rivaroxaban and apixaban. Their advantages include: predictable pharmacokinetics, drug interactions and 
limited food, rapid onset of action and short half-life. However, they lack a specific reversal agent.
Material and Methods: This paper examines the available evidence regarding rivaroxaban and sets out proposals 
for clinical guidance of dental practitioners treating these patients in primary dental care. A literature search was 
conducted through July 2016 for publications in PubMed and Cochrane Library using the keywords “edoxaban”, 
“dabigatran”, “rivaroxaban”, “apixaban”, “new oral anticoagulants”, “novel oral anticoagulants”, “bleeding” and 
“dental treatment” with the “and” boolean operator in the last 10 years.
Results: The number of patients taking edoxaban is increasing. There is no need for regular coagulation monitoring 
of patients on edoxaban therapy. For patients requiring minor oral surgery procedures, interruption of edoxaban is 
not generally necessary.  Management of patients on anticoagulation therapy requires that dentists can accurately 
assess the patient prior to dental treatments. 
Conclusions: Their increased use means that oral care clinicians should have a sound understanding of the me-
chanism of action, pharmacology, reversal strategies and management of bleeding in patients taking edoxaban. 
There is a need for further clinical studies in order to establish more evidence-based guidelines for dental patients 
requiring edoxaban.
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Introduction
There are a large number of patients being treated with 
oral anticoagulants and antiplatelet drugs. Oral anticoa-
gulation and prevention of venous thromboembolism has 
been possible for decades thanks to the use of vitamin K 
antagonists, mainly warfarin and acenocoumarol (1).
Vitamin K antagonist oral anticoagulants have a narrow 
therapeutic window, requiring regular International Nor-
malized Ratio (INR) monitoring, and they also have se-
veral drug-drug and drug-food interactions. These disad-
vantages compromise patients’ quality of life (2).
A great number of medical emergencies as a result of 
bleeding complications, especially in elderly indivi-
duals, are related to the administration of anticoagulant 
drugs that are vitamin K inhibitors. In the USA, these 
drugs are the most frequently involved in such emergen-
cy hospitalizations (3).
Research to find an alternative to classic oral anticoa-
gulants has been focused on the development of an oral 
anticoagulant with a wide therapeutic window and little 
inter- and intra-individual variability that may be admi-
nistered as a fixed-dose with no need for regular coa-
gulation monitoring and few drug-drug and drug-food 
interactions. There are currently three direct factor Xa 
inhibitors (rivaroxaban, apixaban and edoxaban) and one 
direct thrombin inhibitor (dabigatran) with approved in-
dications for antithrombotic prophylaxis and therapy in 
different conditions. Among these, the most recently de-
veloped and marketed oral anticoagulant is edoxaban. 
The ENGAGE AF-TIMI 48 (effective anticoagulation 
with factor Xa next generation in atrial fibrillation) study 
is a randomized double-blind clinical trial that assessed 
the administration of edoxaban vs warfarin on a daily 
basis in a total of 21,105 patients with nonvalvular atrial 
fibrillation. The results proved that the efficacy of war-
farin for the prevention of stroke and systemic embolism 
was noninferior to warfarin, and that the administration 
of edoxaban is associated with less morbidity (lower 
incidence of bleeding) (4). With regard to the ages of 
the patients taking part in the study, both for the risk of 
stroke or systemic embolism, and for major bleeding, 
the results for both doses of edoxaban were consistent, 
regardless of this factor (< 75 vs ≥ 75 years of age).  In 
terms of International Normalized Ratio (INR) control, 
both for the risk of stroke and systemic embolism, and 
for that of major bleeding, the results were consistent for 
both doses of edoxaban, regardless of time in the thera-
peutic range (> 66.4% o ≤ 66.4%), although there was a 
trend in favour of the high dose of edoxaban for lower 
risk of major bleeding in patients with poor INR control 
(5).
Exdoxaban is a direct factor Xa inhibitor with a molecu-
lar weight of 548 Dalton. Its protein binding is approxi-
mately 54% and its bioavailability is 50%. Its half-life is 
around 9-11 hours, and peak plasma levels are reached 
between the first and second hours after administration. 
Its excretion is 35% renal and the rest hepatic (6).
The Food and Drug Administration (FDA) approved the 
use of edoxaban, under the name Savaysa®, in January 
2015, and in June 2015, the European Medicines Agency 
(EMA) authorized its marketing under the name Lixia-
na®. The usual dose is 60 mg every 24 hours, although 
in patients with renal impairment or low body weight 
(under 60 kg) the dose should be halved to 30 mg daily. 
The different cost-effectiveness studies on new oral 
anticoagulants (edoxaban, dabigatran, rivaroxaban and 
apixaban) conducted in several countries are fairly con-
sistent, showing that the administration of these drugs 
seems the best option for patients at increased risk for 
thromboembolic or bleeding complications and those 
with poor anticoagulation control with vitamin K anta-
gonists (7).
Material and Methods
The aim of this paper is to contribute to the discussion 
on how to approach patients taking edoxaban, before, 
during and after dental treatments.
In the present contribution we offer an exhaustive re-
view of the literature found in PubMed and Cochrane 
Library in July 2016. The words used were “edoxaban”, 
“dabigatran”, “rivaroxaban”, “apixaban”, “new oral an-
ticoagulants”, “novel oral anticoagulants”, “bleeding” 
and “dental treatment” with the “and” boolean operator. 
Metaanalyses, systematic reviews, clinical trials and 
case-control studies were considered. Specialized text-
books were also consulted.
Because of their relatively recent introduction, specific 
studies regarding dental treatment of patients taking no-
vel oral anticoagulants are available in literature only 
from 2012.
-Analytical tests
Unlike classic oral anticoagulants that act as vitamin K 
inhibitors, such as warfarin and acenocoumarol, edoxa-
ban does not require regular coagulation tests. However, 
there are certain situations where it may be necessary 
to assess its plasma concentration, such as overdose, 
bleeding or emergency surgery. There are no significant 
changes in the results of routine analytical coagulation 
tests after the administration of edoxaban. Prothrombin 
time and activated partial prothrombin time change ac-
cording to plasma edoxaban concentrations, increasing 
in a dose-dependent manner (8,9).
The best test to assess edoxaban concentrations is the 
measurement of anti-factor Xa (10,11).
-Drug-drug interactions
New oral anticoagulants in general, and edoxaban in 
particular, have few drug-drug interactions. Edoxaban 
is predominantly absorbed in the upper gastrointestinal 
tract, so that drugs or conditions that increase gastric 
emptying and intestinal motility may reduce edoxaban 
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dissolution and absorption. Plasma edoxaban concentra-
tions increase when it is combined with ketoconazole, 
cyclosporine, dronedarone, erythromycin, quinidine or 
verapamil, and its co-administration with rifampicin 
leads to a shortened half-life, with possible decreases in 
its pharmacodynamic effects (12-14).
-Dental management
The prevalence of bleeding complications during invasi-
ve dental procedures is higher in patients taking edoxa-
ban and the rest of new oral anticoagulants (15). There 
are certain dental treatments that require temporary dis-
continuation of edoxaban before beginning.  
There are currently no published studies or protocols in 
scientific literature on the dental management of patients 
taking anticoagulants of the type of edoxaban, so that 
the risk for bleeding should be individually assessed for 
each patient according to their cardiac and haemorrhagic 
condition and the bleeding risk involved in the dental 
procedure to be carried out. While still scarce, there are, 
however, clinical guidelines published in recent years 
that describe the perioperative management of patients 
takin dabigatran, rivaroxaban and apixaban.
Based on the bleeding risk involved in the different 
dental treatments, they can be classified into procedures 
with low bleeding risk and procedures with standard and 
high bleeding risk. 
Procedures with low bleeding risk include oral surgery 
of up to 45 minutes, simple extractions (less than 3 teeth 
in the same session) and periodontal surgery with low 
bleeding risk (15-18). According to the studies publis-
hed on new oral anticoagulants and their dental mana-
gement, dental procedures with low bleeding risk do not 
require discontinuation of edoxaban (16-25).
The rest of dental procedures are associated with stan-
dard and high bleeding risk, and such cases do require 
temporary discontinuation of edoxaban. Since there is 
no scientific basis for discontinuing edoxaban prior to 
Renal function (Clcr in ml/min) Low risk of haemorrhage Medium and high risk 
of haemorrhage
>50 24 hours before 48 hours before
30 - 50 48 hours before 96 hours before
Table 1. Guide to the suppression of edoxaban.
performing dental treatment, when to stop it depends 
on the pharmacokinetics and pharmacodynamics of the 
drug and on the patient’s renal function (impaired renal 
function involves slower clearance of the oral anticoa-
gulant by renal excretion) (20-35). Table 1 shows the 
guidelines for edoxaban discontinuation. 
When to resume edoxaban to re-establish therapeutic an-
ticoagulation depends on the patient’s haemostasis and 
on the bleeding risk involved in the dental treatment. 
In cases of oral surgery with standard bleeding risk, 
edoxaban can be resumed 12-14 hours after the dental 
treatment (23-37).
The treatment of bleeding after dental procedures should 
be individualized according to the severity of the blee-
ding. In cases of mild bleeding, it is enough to use local 
haemostatic measures such as sutures, gelatine or cellulo-
se sponges and tranexamic acid mouthwashes, which help 
to reduce the chance of postoperative bleeding (17-40).
Conclusions
In dentistry and oral surgery, the major concerns in 
treatment of patients taking oral anticoagulants or anti-
platelet drugs is the risk of haemorrhage
There are several novel oral anticoagulant agents (edoxa-
ban, dabigatran, rivaroxaban and apixaban) that are be-
ing increasingly used as an alternative to warfarin and 
acenocoumarol.
For patients requiring simple dental extraction or minor 
oral surgery procedures, interruption of edoxaban is not 
generally necessary, while an higher control of bleeding 
and discontinuation of the drug should be requested be-
fore invasive surgical procedures.
The heath professionals have to consider that the number 
of patients taking edoxaban is increasing. Since availa-
ble data are not sufficient to establish an evidence-based 
dental management, the dentist must use caution and at-
tention when treating patients taking edoxaban.
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